Applied Genetic Technologies Priced, Nasdaq: AGTC
Biotech developing gene therapies for orphan eye diseases.
Industry: Health Care
First Day Return: +23.0%
AGTC
Biotech developing gene therapies for orphan eye diseases.
| IPO Data | |
|---|---|
| IPO Date | 03/26/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Alachua, FL, United States |
| Founded | 1999 |
| Employees at IPO | 17 |
| Website www.agtc.com | |
IPO News for Applied Genetic Technologies
Applied Genetic Technologies (AGTC) Performance
